The company holds a 99.99% stake in the subsidiary. Alembic Lifesciences Philippines Inc. has an authorised share capital of 12 million Philippine pesos, divided into 1.2 million shares of 10 Philippine pesos each.
Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets. The company’s consolidated net profit fell 3.9% to Rs 132.97 crore despite a 10.8% jump in net sales to Rs 1,876.31 crore in Q3 FY26 over Q3 FY25.
Click here to visit SEBI Scores